Thu Sep 26 14:00:00 UTC 2024: ## Pharmaceutical Payments to Breast Cancer Specialists in Japan Surge, Raising Concerns About Conflicts of Interest

**Tokyo, Japan – September 26, 2024** – A new study published in PLOS ONE reveals a concerning trend of escalating pharmaceutical payments to breast cancer specialists in Japan. The research, conducted by a team of researchers from various institutions across Japan, analyzed financial relationships between pharmaceutical companies and specialists from 2016 to 2019.

The study found that total payments reached a staggering USD 13,329,911, growing at an average annual rate of 10.1%. This increase coincided with the introduction of new breast cancer drugs, particularly CDK4/6 inhibitors like palbociclib and abemaciclib, with companies like Pfizer Japan and Eli Lilly Japan significantly increasing their payments after these drug launches.

However, the distribution of payments is highly skewed, with a small group of specialists receiving a disproportionately large share. The Gini index, a measure of income inequality, reached 0.994, indicating a high level of concentration.

This trend raises concerns about potential conflicts of interest and their influence on clinical decision-making and guideline recommendations. The study authors point to the fact that the 2022 Breast Cancer Guidelines in Japan continue to recommend drugs like atezolizumab and bevacizumab, despite their withdrawal from the market in the United States due to unconfirmed efficacy.

The study also highlights the potential impact of pharmaceutical payments on gender disparities within the field of breast surgery in Japan. The authors note that the male-dominated nature of the field is partly influenced by the reliance on sponsored lectures and events, often held at inconvenient times for female physicians.

The study concludes that while transparency initiatives are necessary, they are not sufficient to address the negative impacts of pharmaceutical payments. The authors call for further measures, such as setting caps on payments to key figures in professional societies and guideline committees, to ensure ethical and unbiased decision-making in the breast cancer field.

Read More